# Puma Biotechnology, Inc. (PBYI)

> Source: Nexqual · https://nexqual.com/PBYI · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Puma Biotechnology, Inc. (PBYI), nexqual.com/PBYI" · informational, not investment advice.

**Price:** USD 10.54 (-0.75% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 10.62 · day 10.51–10.81 · 52w 4.58–11.5 · market cap $544M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $231M, net income $26.7M (11.6% margin), free cash flow $41.1M (SEC filings).
- Valuation: P/E 20.4x (avg 8.0x at the last 3 fiscal year-ends), EV/EBITDA 11.9x, net cash $86.8M.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts).
- Total return with dividends: 1Y +94.5% vs S&P 500 +14.8%; 5Y +106.7% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD —, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: PBYI paid no cash dividend in the last five years.
- Short interest: 10.30% of float (as of 2026-10-15), 13.8 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $253M | $228M | $236M | $230M | $228M | $231M |
| Gross profit | $189M | $173M | $173M | $166M | $170M | — |
| Operating income | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M | $30.4M |
| Net income | -$29.1M | $2K | $21.6M | $30.3M | $31.1M | $26.7M |
| EPS (diluted) | -$0.72 | $0.00 | $0.45 | $0.62 | $0.61 | — |
| Free cash flow | $20.6M | -$15.8M | $26.9M | $38.9M | $41.7M | $41.1M |
| Gross margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% | — |
| Operating margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% | 13.2% |
| Net margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% | 11.6% |
| Revenue growth | +12.5% | -9.9% | +3.3% | -2.2% | -0.9% | — |
| Cash + short-term investments | $69.8M | $46.5M | $48.9M | $86.8M | $91.6M | — |
| Total debt | $102M | $102M | $102M | $68.0M | $22.7M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 20.4x · P/S 2.4x · EV/EBITDA 11.9x · EV/Sales 2.0x · P/FCF 13.2x · P/B 3.9x · FCF yield 7.56% · Earnings yield 4.91% · Net cash $86.8M · EV $457M
P/E at fiscal year-ends: Dec 2025 9.7x, Dec 2024 4.9x, Dec 2023 9.5x.

## Analysts
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts.
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | TD Cowen | Target raised | Hold | $5 → $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +94.5% | +106.7% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +95.3% | +15.6% |
| Volatility (annualized) | 60.9% | 70.4% |
| Max drawdown | -25.8% (Feb 2026→Feb 2026) | -68.3% (Feb 2024→Sep 2024) |

## Dividends
PBYI paid no cash dividend in the last five years.

## Short interest
4,540,314 shares sold short, 10.30% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 4,319,663 shares (+5.1%). Days to cover: 13.8 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/PBYI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2026-12-31) | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $0 | — |
| Next fiscal year (ends 2027-12-31) | — | — | — | $0 | — |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.20 | $0.07 | Beat +185.7% | — |
| — | Quarter ended Mar 31, 2026 | −$0.04 | −$0.13 | Beat +69.2% | — |
| — | Quarter ended Dec 31, 2025 | $0.29 | $0.23 | Beat +26.1% | — |
| — | Quarter ended Sep 30, 2025 | $0.21 | $0.09 | Beat +133.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).